CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 35 enrolled
Drug / intervention
Interleukin-2drug
Likely dose
Interleukin-2 6 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01366092
NCT01366092Phase 2Active
CompareCT.gov

A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease

Dana-Farber Cancer Institute·interventional·Posted Jun 3, 2011·Updated Feb 20, 2026

In Brief

A Phase 2 clinical trial evaluating Interleukin-2 for Chronic Graft-versus-host Disease. Active but no longer recruiting, targeting 35 participants across 3 sites.

Detailed Summary

Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it. This process is known as graft-versus-host-disease. It is thought that IL-2 may help control chronic GVHD by stopping the donor's immune system from 'rejecting' your body. In this research study, we are looking to see how IL-2 can be used in combination with steroids to treat cGVHD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Graft-versus-host Disease
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Prometheus Laboratories

Timeline

Phase 2Active
20112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 3, 2011
Enrollment StartJul 1, 2011
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.1 years ago

Interventions

Interleukin-2drug

Daily subcutaneous IL-2 (1 x 10\^6 IU/m\^2/day) for self-administration for 12 weeks followed by 4-week hiatus